AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Stoke Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00JPCBPH8
25.04▼ 0.66 (-2.57%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
25.70
Day's Range
24.80 – 25.83
52-Week Range
20.32 – 42.44
Volume
1.6M
Avg Volume
899.4K
Share Statistics
Shares Outstanding
Employees
170
Exchange
XNAS
Listed
2019-06-19
Share count as of July 30, 2026

Stoke Therapeutics, Inc. Common Stock (STOK) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Stoke Therapeutics, Inc. Common Stock (STOK)
What is Stoke Therapeutics, Inc. Common Stock's Market Cap?
Stoke Therapeutics, Inc. Common Stock's Market Cap is $1.6B, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's Enterprise Value?
Stoke Therapeutics, Inc. Common Stock's Enterprise Value is $1.5B, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's Price / Sales?
Stoke Therapeutics, Inc. Common Stock's Price / Sales is 58.6×, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's EV / Revenue?
Stoke Therapeutics, Inc. Common Stock's EV / Revenue is 54.6×, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's EV / EBITDA?
Stoke Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's Revenue (TTM)?
Stoke Therapeutics, Inc. Common Stock's Revenue (TTM) is $27.6M, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's Net Income (TTM)?
Stoke Therapeutics, Inc. Common Stock's Net Income (TTM) is -$207.9M, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's EBITDA?
Stoke Therapeutics, Inc. Common Stock's EBITDA is -$221.6M, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Stoke Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -3.22, based on as-reported figures from SEC (XBRL) filings.
What is Stoke Therapeutics, Inc. Common Stock's EBITDA Margin?
Stoke Therapeutics, Inc. Common Stock's EBITDA Margin is -803.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · STOKAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-32.5%-96.1%-93.8%+117.2%
Operating expenses:
Research and development
Sales, general and administrative
Total operating expenses
% of revenue801.7%957.6%4482.2%505.3%
(Loss) income from operations
% of revenue-701.7%-857.6%-4382.2%-405.3%
Other income (expense):
Interest income (expense), net
Other income
Total other income (expense)
(Loss) income before income taxes—
Provision for income taxes—
Net (loss) income
% of revenue-660.8%-802.7%-4132.2%-360.7%
Net (loss) income per share:
Basic
Diluted—
Comprehensive (loss) income:
Net (loss) income——
% of revenue-660.8%-802.7%——
Other comprehensive (loss) gain:
Unrealized (loss) gain on marketable securities
Total other comprehensive (loss) gain
Comprehensive (loss) income